A descriptive, open-label, long-term follow-up survey of psychotic patients receiving risperidone long-acting injectable: Preliminary results.

Objective. To assess clinical development in patients with psychotic disorders who received risperidone long-acting injectable (RLAI) in combination with psychosocial interventions as part of daily clinical practice in France. Methods.